Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic

A Tsimanis1, L Shvidel, A Klepfish

  • 1Department of Hematology, Kaplan Medical Center, POB 1, Rehovot, 76100, Israel. Yehudats@netvision.net.il

Leukemia & Lymphoma
|November 9, 2001
PubMed

Insights

The IL-11/IL-11R alpha system is constitutively expressed in B-chronic lymphocytic leukemia (B-CLL) cells. This system activates B-CLL cells, suggesting a key role in the disease pathogenesis.

Area of Science:

  • Immunology
  • Hematology
  • Molecular Biology

Background:

  • Cytokines are implicated in the pathogenesis of B-chronic lymphocytic leukemia (B-CLL).
  • The specific role of IL-11 and its receptor (IL-11R alpha) in B-CLL requires further elucidation.

Purpose of the Study:

  • To investigate the expression and function of IL-11 and IL-11R alpha in B-CLL cells.
  • To determine the impact of IL-11 on B-CLL cell activation, proliferation, and survival.

Main Methods:

  • Reverse-transcriptase polymerase chain reaction (RT-PCR) for gene expression analysis.
  • FACS analysis and immunofluorescence for protein expression and localization.
  • Treatment of B-CLL cells with recombinant human IL-11 (rhIL-11) and dexamethasone.

Main Results:

  • Constitutive expression of IL-11 and IL-11R alpha was observed in B-CLL cells.
  • IL-11R alpha expression was significantly higher in B-CLL cells compared to normal peripheral blood lymphocytes (PBL).
  • rhIL-11 activated B-CLL cells, inducing morphological changes and increasing cell number and size, without affecting short-term survival or resistance to dexamethasone.

Conclusions:

  • The IL-11/IL-11R alpha system is constitutively expressed in B-CLL cells.
  • IL-11 plays a role in activating malignant B-CLL cells.
  • These findings suggest a critical involvement of the IL-11/IL-11R alpha pathway in B-CLL pathogenesis.